Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that … Read more
Nanexa AB (NANEXA) - Net Assets
Latest net assets as of December 2025: Skr101.53 Million SEK
Based on the latest financial reports, Nanexa AB (NANEXA) has net assets worth Skr101.53 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr138.14 Million) and total liabilities (Skr36.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr101.53 Million |
| % of Total Assets | 73.5% |
| Annual Growth Rate | 46.97% |
| 5-Year Change | -32.89% |
| 10-Year Change | 498.51% |
| Growth Volatility | 113.26 |
Nanexa AB - Net Assets Trend (2014–2025)
This chart illustrates how Nanexa AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanexa AB (2014–2025)
The table below shows the annual net assets of Nanexa AB from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr101.53 Million | +43.15% |
| 2024-12-31 | Skr70.92 Million | -25.99% |
| 2023-12-31 | Skr95.83 Million | -12.16% |
| 2022-12-31 | Skr109.10 Million | -27.89% |
| 2021-12-31 | Skr151.29 Million | +249.00% |
| 2020-12-31 | Skr43.35 Million | +74.25% |
| 2019-12-31 | Skr24.88 Million | +52.74% |
| 2018-12-31 | Skr16.29 Million | -40.68% |
| 2017-12-31 | Skr27.46 Million | +61.85% |
| 2016-12-31 | Skr16.96 Million | +179.70% |
| 2015-12-31 | Skr6.07 Million | +312.87% |
| 2014-12-31 | Skr1.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanexa AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33590404200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr20.57 Million | 20.26% |
| Other Comprehensive Income | Skr64.50 Million | 63.53% |
| Other Components | Skr356.94 Million | 351.56% |
| Total Equity | Skr101.53 Million | 100.00% |
Nanexa AB Competitors by Market Cap
The table below lists competitors of Nanexa AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Osaka Steel Co., Ltd.
PINK:OSKXF
|
$39.34 Million |
|
Immutep Ltd
AU:IMM
|
$39.35 Million |
|
Lifevantage Corporation
NASDAQ:LFVN
|
$39.36 Million |
|
KTIS Corporation
KO:058860
|
$39.36 Million |
|
Playmates Holdings Limited
PINK:PYHOF
|
$39.34 Million |
|
Shandong Zhonglu Oceanic Fisheries Co Ltd
SHE:200992
|
$39.33 Million |
|
Raonsecure Co. Ltd
KQ:042510
|
$39.33 Million |
|
PT Cakra Buana Resources Energ
JK:CBRE
|
$39.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanexa AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 70,925,000 to 101,531,000, a change of 30,606,000 (43.2%).
- Net loss of 11,388,000 reduced equity.
- New share issuances of 46,738,000 increased equity.
- Other comprehensive income increased equity by 13,180,000.
- Other factors decreased equity by 17,924,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-11.39 Million | -11.22% |
| Share Issuances | Skr46.74 Million | +46.03% |
| Other Comprehensive Income | Skr13.18 Million | +12.98% |
| Other Changes | Skr-17.92 Million | -17.65% |
| Total Change | Skr- | 43.15% |
Book Value vs Market Value Analysis
This analysis compares Nanexa AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.56x to 5.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.39 | Skr3.71 | x |
| 2015-12-31 | Skr1.08 | Skr3.71 | x |
| 2016-12-31 | Skr2.46 | Skr3.71 | x |
| 2017-12-31 | Skr3.21 | Skr3.71 | x |
| 2018-12-31 | Skr1.33 | Skr3.71 | x |
| 2019-12-31 | Skr1.58 | Skr3.71 | x |
| 2020-12-31 | Skr2.03 | Skr3.71 | x |
| 2021-12-31 | Skr4.25 | Skr3.71 | x |
| 2022-12-31 | Skr2.15 | Skr3.71 | x |
| 2023-12-31 | Skr1.37 | Skr3.71 | x |
| 2024-12-31 | Skr0.52 | Skr3.71 | x |
| 2025-12-31 | Skr0.65 | Skr3.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanexa AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.50%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.36x
- Recent ROE (-11.22%) is above the historical average (-47.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -63.17% | -62.66% | 0.57x | 1.76x | Skr-1.07 Million |
| 2015 | -68.03% | -626.39% | 0.08x | 1.28x | Skr-4.73 Million |
| 2016 | -37.43% | -2267.50% | 0.01x | 1.21x | Skr-8.05 Million |
| 2017 | -29.03% | -7591.43% | 0.00x | 1.21x | Skr-10.72 Million |
| 2018 | -68.57% | -3503.01% | 0.01x | 1.71x | Skr-12.80 Million |
| 2019 | -52.05% | -757.31% | 0.05x | 1.42x | Skr-15.44 Million |
| 2020 | -50.14% | -918.29% | 0.04x | 1.24x | Skr-26.07 Million |
| 2021 | -23.79% | -1516.39% | 0.01x | 1.09x | Skr-51.13 Million |
| 2022 | -53.69% | -2047.94% | 0.02x | 1.56x | Skr-69.48 Million |
| 2023 | -79.72% | -260.50% | 0.22x | 1.38x | Skr-85.98 Million |
| 2024 | -35.11% | -102.23% | 0.27x | 1.29x | Skr-32.00 Million |
| 2025 | -11.22% | -31.50% | 0.26x | 1.36x | Skr-21.54 Million |
Industry Comparison
This section compares Nanexa AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $94,188,824
- Average return on equity (ROE) among peers: -61.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanexa AB (NANEXA) | Skr101.53 Million | -63.17% | 0.36x | $39.34 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $21.33 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $549.55K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $14.51 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $570.29K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.01 Million |